Although the complex immune mechanisms of BJIKT involved in MDSCs and their regulation of TILs are needed to further explore, the synergistic antitumor effect of BJIKT and anti-PD-L1 antibody offers a reasonable strategy for future clinical combinatorial application to overcome the low response in patients with CRC. Here, CD274 is linked to colorectal carcinoma.